Navigation Links
2-drug combination appears safe and active in metastatic kidney cancer
Date:5/31/2009

ORLANDO (May 31, 2009)Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

Elizabeth Plimack, M.D., M.S., a medical oncologist and attending physician at Fox Chase will report the trial results on Sunday, May 31 at the annual meeting of the American Society of Clinical Oncology.

"We have certainly seen sustained responses with this combination which are encouraging," Plimack says.

One of the patients with an extended response has papillary renal cell cancer, which is a rare form of the disease that does not respond well to standard therapies. "Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib and sorafenib, as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that this combination may be active to some degree for them."

mTOR signaling promotes tumor cell proliferation and blood vessel development. Temsirolimus (Torisel), blocks signaling through one portion of the mTOR signaling complex, called TORC1, and slows tumor progression in patients with advanced kidney cancer. However, a second portion of the complex, called TORC2, is unaffected by temsirolimus and continues to promote cell proliferation. Therefore, Plimack and colleagues suspect that blocking TORC2 signaling activity could improve patient outcomes. Bryostatin blocks a downstream effector of TORC2, called protein kinase C.

Plimack and colleagues designed the phase I trial to test the safety of the bryostatin-temsirolimus combination. Twenty-five patients enrolled in the trial, including 20 patients with renal cell carcinoma. The phase I trial tested a combination of 20 micrograms/m2 bryostatin weekly plus one of the following temsirolimus doses, 10, 15, 25, or 37.5 mg, every 28 days.

The combination appears to be well tolerated in renal cell patients. Two patients developed dose limiting toxicities (one with renal toxicity and one with neutropenia) at the highest temsirolimus dose. Enrollment is now continuing with patients receiving 25 mg temsirolimus. (Two of the non-renal cell cancer patients developed dose-limiting toxicities early in the trial, after which point the investigators limited enrollment to patients who had not received prior chemotherapy.)

Early responses in renal cell cancer patients are promising, according to Plimack. Three patients have had durable partial responses to therapy. Two of those individuals are off therapy and have partial responses continuing at 3+ years and 12+ months, and a third patient continues on therapy with a partial response extending beyond 22 months.

Enrollment in the trial is on-going and complete data will be provided at the meeting.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. 2-drug blood pressure therapy lowers cardiovascular risk
2. New treatment combination proves safe for head and neck cancer patients
3. Study shows drug combination improves outcome for advanced non-small cell lung cancer
4. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
5. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
6. Transplant Surgery and Identity: A Discussion Among Pioneers with Unusual Combinations of Interests, Skills and Talents
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc.
9. Triple drug combination is promising option to treat metastatic HER2+ breast cancer
10. Plavix, Heartburn Drugs May Be Risky Combination
11. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... IL (PRWEB) , ... May 31, 2016 , ... The ... and executive committee members: , David G. Lewallen, MD, began his term as ... past president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on ... broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate ... calls the country’s “modern medical money maelstrom.” , During the interview with Mr. ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... apply information technology solutions to the healthcare industry, The University of Scranton is ... offers an accelerated path to a career in rapidly growing field of healthcare ...
(Date:5/30/2016)... ... May 30, 2016 , ... "This plugin comes with ... Austin - CEO of Pixel Film Studios. , TransPack Volume 7 features ... Choose from abstract transitions to more simple wipes with blur & drop shadow ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... ZIONA, Israel , May ... regenerative medicine company utilizing its proprietary plant-based rhCollagen technology ... received authorization from the Chief Scientist of ... 50% of its NIS 12 million development project for ... measurably higher than last year,s authorized grant, which totaled ...
(Date:5/31/2016)... -- 194 Mitgliedsstaaten verpflichten sich ... viraler Hepatitis    Am 28. Mai ... Hepatitis bis 2030 zu eliminieren. Bei der ... sich die Staaten einstimmig dafür entschieden, die erste ... Strategy) zu verabschieden, was das bisher weltweit größte ...
Breaking Medicine Technology: